Herein, AML is further subclassified into: (i) AML with recurrent genetic abnormalities (including t(8;21); inv(16); PML-RARA; t(9;11); t(6;9); inv(3); t(1;22); BCR-ABL; nucleophosmin (NPM1) mutations; biallelic CEBPA mutations and AML with RUNX1 mutations as a provisional entity), (ii) AML with myelodysplasia related changes, (iii) therapy related myeloid neoplasm, (iv) AML, not otherwise specified, (v) myeloid sarcoma and (vi) myeloid proliferations related to Down Syndrome. This evidence concerns the gene RUNX1 and Myelodysplasia.